Skip to main content
main-content

Kidney cancer

16-03-2017 | Kidney cancer | News | Article

High-risk clear cell RCC survival not ASSUREd with sunitinib, sorafenib

Adjuvant treatment with sunitinib or sorafenib does not prolong disease-free survival or overall survival in clear cell renal cell carcinoma patients classed as high risk, shows a post hoc analysis of the placebo-controlled ASSURE trial.

Source:

JAMA Oncol 2017; Advance online publication

19-10-2016 | Kidney cancer | News | Article

Cabozantinib ‘potential first-line option’ for advanced RCC

Cabozantinib significantly improves progression-free survival in newly diagnosed patients with intermediate- or poor-risk metastatic renal cell carcinoma, shows a head-to-head comparison with the standard of care sunitinib.

Source:

ESMO 2016; Copenhagen, Denmark

17-06-2016 | Kidney cancer | News | Article

News in brief

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus.

31-03-2016 | Kidney cancer | News | Article

News in brief

Genomic clue to ethnic disparities in clear cell RCC survival

The poorer survival outcomes for African–American versus White patients with clear cell renal cell carcinoma could be explained by inherent differences in tumour genomics, indicate findings published in JAMA Oncology.

21-01-2016 | Kidney cancer | News | Article

Editor's pick

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics.

Source:

Lancet Oncol 2016; Advance online publication

15-01-2016 | Kidney cancer | News | Article

PD-L1 inhibition well-tolerated, active in metastatic RCC

The programmed death-ligand 1 inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma, according to phase Ia trial findings.

Source:

J Clin Oncol 2016; Advance online publication

image credits